Galapagos Receives €2.3 Million IWT Grant for Fibrosis Research
News Feb 04, 2014
Galapagos NV has announced that it has been awarded a €2.3 million grant for research in fibrosis from the Flemish agency for Innovation by Science and Technology (IWT).
The goal of this 2-year project is to create a new research platform by integrating knowledge from a range of fibrotic diseases, including lung, kidney, liver, and skin fibrosis. This new platform will support Galapagos' efforts to develop novel drug candidates in fibrosis.
Galapagos has a fully proprietary portfolio of fibrosis drug targets and molecules. The major aim of this IWT grant is to deliver a comprehensive fibrosis research platform, building on existing tools and considerable expertise within Galapagos and a number of academic laboratories.
By integrating data obtained from pre-clinical and clinical research in several fibrotic diseases with similar root causes, Galapagos aims to create a unique fibrosis research environment, allowing for better selection of targets and molecules for the design of novel treatments in this area.
Academic partners for the project include Prof Dr Wuyts (Pneumology, KU Leuven), Prof Dr Naesens and Prof Dr Kuypers (Nephrology, KU Leuven), Prof Dr Van Vlierberghe (Hepatology, U Ghent), Prof Dr F. De Keyser and Dr Smith (Scleroderma, U Gent) and Prof van Grunsven (Hepatology, VU Brussels).
"Galapagos is very pleased with this financial support from the IWT for our research in fibrosis, an area with very high unmet patient need and one in which Galapagos already has performed ground-breaking work," said Dr Piet Wigerinck, Chief Scientific Officer of Galapagos.
University of Wisconsin–Madison Professor of Chemistry Shannon Stahl has received the Steenbock Professorship in Chemical Sciences. In addition to advancing the fundamental science in this area, Stahl has been involved in numerous industrial collaborations that have led to practical applications, including target applications relevant to pharmaceutical synthesis.READ MORE